The structure of human recombinant aldose reductase complexed with the potent inhibitor zenarestat

被引:49
|
作者
Kinoshita, T
Miyake, H
Fujii, T
Takakura, S
Goto, T
机构
[1] Fujisawa Pharmaceut Co Ltd, Exploratory Res Labs, Tsukuba, Ibaraki 3002698, Japan
[2] Fujisawa Pharmaceut Co Ltd, Med Biol Res Labs, Yodogawa Ku, Osaka 5328514, Japan
关键词
D O I
10.1107/S0907444902002378
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The crystal structure of the complex of human recombinant aldose reductase (AR) with zenarestat, one of its potent inhibitors, has been solved at 2.5 Angstrom resolution. Zenarestat fits neatly in the hydrophobic active site and induces unique and dramatic conformational changes. For example, the benzene ring of zenarestat occupies a gap in the side chains of Leu300 and Trp111 that interact directly and forms a CH-pi interaction in the native holoenzyme. As a result, the benzene ring of the inhibitor and these side chains form a CH-pi-pi interaction. Such structural information is key to understanding the mode of action of this class of inhibitors and for rational design of better therapeutics.
引用
收藏
页码:622 / 626
页数:5
相关论文
共 50 条
  • [21] STRUCTURE OF THE HUMAN ALDOSE REDUCTASE GENE
    GRAHAM, A
    BROWN, L
    HEDGE, PJ
    GAMMACK, AJ
    MARKHAM, AF
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1991, 266 (11) : 6872 - 6877
  • [22] THE EFFECT OF NONENZYMATIC GLYCATION ON RECOMBINANT HUMAN ALDOSE REDUCTASE
    YAMAOKA, T
    ODA, A
    BANNAI, C
    ITAKURA, M
    YAMASHITA, K
    DIABETES RESEARCH AND CLINICAL PRACTICE, 1995, 27 (03) : 165 - 169
  • [23] Identification of new potent inhibitor of aldose reductase from Ocimum basilicum
    Bhatti, Huma Aslam
    Tehseen, Yildiz
    Maryam, Kiran
    Uroos, Maliha
    Siddiqui, Bina S.
    Hameed, Abdul
    Iqbal, Jamshed
    BIOORGANIC CHEMISTRY, 2017, 75 : 62 - 70
  • [24] DEVELOPMENT OF POTENT ALDOSE REDUCTASE INHIBITORS HAVING A HYDANTOIN STRUCTURE
    MIWA, I
    HIRANO, M
    INAGAKI, K
    BELBEOCH, C
    OKUDA, J
    BIOCHEMICAL PHARMACOLOGY, 1987, 36 (17) : 2789 - 2794
  • [25] HUMAN SAFETY PROFILE OF TOLRESTAT - AN ALDOSE REDUCTASE INHIBITOR
    RYDER, S
    SAROKHAN, B
    SHAND, DG
    MULLANE, JF
    DRUG DEVELOPMENT RESEARCH, 1987, 11 (02) : 131 - 143
  • [26] KINETIC CHARACTERISTICS OF ZENECA ZD5522, A POTENT INHIBITOR OF HUMAN AND BOVINE LENS ALDOSE REDUCTASE
    COOK, PN
    WARD, WHJ
    PETRASH, JM
    MIRRLEES, DJ
    SENNITT, CM
    CAREY, F
    PRESTON, J
    BRITTAIN, DR
    TUFFIN, DP
    HOWE, R
    BIOCHEMICAL PHARMACOLOGY, 1995, 49 (08) : 1043 - 1049
  • [27] Synthesis of the human aldose reductase inhibitor rubrolide L
    Boukouvalas, John
    McCann, Lucas C.
    TETRAHEDRON LETTERS, 2010, 51 (35) : 4636 - 4639
  • [28] Pharmacological properties of fidarestat, a potent aldose reductase inhibitor, clarified by using sorbitol in human and rat erythrocytes
    Sobajima, H
    Aoki, T
    Sassa, H
    Suzuki, T
    Taniko, K
    Makino, M
    Mizuno, K
    Suzuki, T
    PHARMACOLOGY, 2001, 62 (04) : 193 - 199
  • [29] Inhibitory effect of chalcone derivatives on recombinant human aldose reductase
    Iwata, S
    Nagata, N
    Omae, A
    Yamaguchi, S
    Okada, Y
    Shibata, S
    Okuyama, T
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 1999, 22 (03) : 323 - 325
  • [30] X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP+ and the potent aldose reductase inhibitor fidarestat: Implications for inhibitor binding and selectivity
    Xavier Ruiz, Francesc
    Cousido-Siah, Alexandra
    Mitschler, Andre
    Farres, Jaume
    Pares, Xavier
    Podjarny, Alberto
    CHEMICO-BIOLOGICAL INTERACTIONS, 2013, 202 (1-3) : 178 - 185